Actively Recruiting
RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis
Led by Hospital Clinic of Barcelona · Updated on 2025-09-08
64
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The implementation of a non-pharmacological multimodal intervention program-including physical exercise, nutritional counseling, and psychological support-is expected to improve fatigue in patients with primary biliary cholangitis. Consequently, this improvement is anticipated to enhance quality of life and cognitive symptoms, while also positively impacting emotional, social, and occupational aspects. From a pathophysiological perspective, it is hypothesized that chronic cholestasis and/or immune system activation, with the release of pro-inflammatory cytokines, leads to both central and peripheral alterations causing fatigue. At the central level, systemic inflammation may induce neuronal senescence in the basal ganglia, resulting in altered functional connectivity networks dependent on these regions and/or structural and connectivity changes in areas involved in interoception, such as the insula and anterior cingulate cortex. At the peripheral level, the hypothesis is that chronic inflammation mediated by anti-mitochondrial antibodies causes mitochondrial metabolic dysfunction in muscle cells, which would be reflected in changes observed in the gene expression analysis of these cells. Improvement in fatigue following the multimodal intervention program is expected to be associated with normalization of the immunological profile, enhanced functional brain connectivity, and improved mitochondrial metabolism in muscle.
CONDITIONS
Official Title
RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with primary biliary cholangitis according to EASL guidelines
- Moderate to severe fatigue defined by 29 points or more on the PBC-40 questionnaire
You will not qualify if you...
- Older than 80 years
- Severe itching (pruritus)
- Decompensated cirrhosis
- Liver diseases other than PBC
- Liver transplant or on liver transplant waiting list
- Uncontrolled thyroid disease
- Anemia with hemoglobin less than 11 g/dl
- Uncontrolled cardiovascular risk factors
- Body mass index over 35
- Acute heart attack or unstable angina in the past 6 months
- Muscle or systemic diseases affecting muscles
- Dysautonomia
- Untreated osteoporosis
- Untreated celiac disease
- Alcohol consumption over 14 standard drinks per week for women and over 21 for men
- Chronic kidney disease stage 4 or higher
- Cancer in the past 2 years (except non-melanoma skin cancer and in situ cervical carcinoma)
- Unable to perform or follow the prehabilitation program
- Participation in another clinical trial in the last 2 months
- Refusal to give informed consent
- For fatigue pathophysiology study: severe depression or neuropsychiatric disease
- Treatment with central nervous system-acting drugs
- Muscle or systemic diseases that may involve muscles
- Immunosuppressive treatment
- Sleep disorders
- Obesity with body mass index over 30
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain, 08036
Actively Recruiting
Research Team
H
Helena Hernández Évole, MD
CONTACT
S
Sergio Rodríguez Tajes, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here